ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LYEL vs QTTB // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Lyell Immunopharma Inc. (NASDAQ) VS. Q32 Bio Inc. (NASDAQ) • 15-METRIC TALLY: LYEL 2 — QTTB 4
■ METRIC PARITY
options-implied-move
—
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LYEL VS. QTTB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LYEL QTTB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 QTTB /roic <GO>
EV/EBITDA & P/E Valuation — 12.8x — TIE /valuation <GO>
Free Cash Flow Yield — -12.70% — TIE /fcf-yield <GO>
Operating Margin -60.00% 31.50% -91.50 QTTB /operating-margins <GO>
Net Profit Margin -60.00% 55.50% -115.50 QTTB /net-margins <GO>
Revenue Growth (YoY) -41.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 5.99 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 4/9 -1.00 QTTB /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 60.0 48.2 +11.80 LYEL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 8.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $270.5M $265.2M $5.3M LYEL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LYEL REV QTTB REV LYEL GROSS % QTTB GROSS % LYEL FCF QTTB FCF
FY 2025 $36.0K $53.7M — — -$150.8M -$33.5M
FY 2024 $61.0K $185.1M — — -$162.9M -$67.8M
FY 2023 $130.0K $1.2M — — -$163.7M -$18.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LYEL // BETA —
QTTB // BETA —